Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Brigimadlin by Boehringer Ingelheim International for Metastatic Biliary Tract Cancer: Likelihood of Approval
Brigimadlin is under clinical development by Boehringer Ingelheim International and currently in Phase II for Metastatic Biliary Tract Cancer. According...
Brigimadlin by Boehringer Ingelheim International for Soft Tissue Sarcoma: Likelihood of Approval
Brigimadlin is under clinical development by Boehringer Ingelheim International and currently in Phase I for Soft Tissue Sarcoma. According to...
Brigimadlin by Boehringer Ingelheim International for Dedifferentiated Liposarcoma: Likelihood of Approval
Brigimadlin is under clinical development by Boehringer Ingelheim International and currently in Phase III for Dedifferentiated Liposarcoma. According to GlobalData,...
Brigimadlin by Boehringer Ingelheim International for Non-Small Cell Lung Cancer: Likelihood of Approval
Brigimadlin is under clinical development by Boehringer Ingelheim International and currently in Phase I for Non-Small Cell Lung Cancer. According...